Bioconjugation presents an new frontier for pharmaceutical development, providing an option for improved drug efficacy across ...

The FDA approval was based on results from the CABINET study, a phase 3 pivotal trial evaluating cabozantinib compared with placebo in two groups of patients with previously treated NETs: advanced ...

If you would like to learn more about the IAEA’s work, sign up for our weekly updates containing our most important news, multimedia and more.

Radiotherapy is an emerging treatment for melanoma, but conventional beta-emitting radionuclide ... 1 receptors (MC1R), which are overexpressed in melanoma cells. "Since the tagged peptide was ...

While Novartis and Bayer got there first, AstraZeneca, Bristol Myers Squibb and Eli Lilly are all vying to bring their ...

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors ...

confirms and reassures what neuroendocrine tumor specialists have witnessed and believed for some time: radionuclide therapy using ... somatostatin receptor-targeting radiopharmaceuticals should ...

Radiotherapy is an emerging treatment for melanoma, but conventional beta-emitting radionuclide ... 1 receptors (MC1R), which are overexpressed in melanoma cells. "Since the tagged peptide was ...